Skip to main content

Table 1 Baseline characteristics of 60 patients with new-onset polyarticular JIA

From: Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial

 IFX+ MTXTripleMTXp
Age (yrs)10.5 (4.5—14.9)8.2 (4.8—13.3)10.1 (4.0—14.4)0.06
Female (%)14 (70)14 (70)11 (55)0.21
Time (months) from disease onset0.82 (0.0-2.7)1.77 (0.03—7.0)1.18 (0.03—7.1)0.20
Rheumatoid factor positive01 (5)0 
JIA subtype
 Polyarthritis, seronegative19 (95)16 (80)15 (75) 
 Enthesitis-related arthritis (%)1 (5)3 (15)4 (20) 
 Polyarthritis, seropositive01 (5)0 
 Psoriatic arthritis001 (5) 
CHAQ0.49 (0—1.75)0.71 (0—2.00)1.07 (0—1.88)0.01
JADAS1017.1 (6.9—23.4)20.1 (9.8—29.8)21.9 (11.4—30.6)0.01
Pain-VAS24.5 (0—90)37.6 (4—78)46.7 (2—85)0.02
PhS28.2 (21.4—35.1)28.8 (17.9—39.6)21.9 (12.8—30.9)0.46
PsS51.4 (27.1—58.5)48.9 (37.1—62.8)52.8 (40.2—65.8)0.28
  1. Values are presented as mean (range), unless otherwise stated. IFX+MTX: infliximab+methrotrexate; Triple: Triple therapy of sulphasalazine, hydroxychloroquine, and methotrexate; MTX: methotrexate; CHAQ child health assessment questionnaire, JADAS juvenile arthritis disease activity score, VAS visual analoque scale, PhS Physical summary Score, PsS Psychosocial summary Score